IMAP France advises BIOGROUP on the acquisition of the Laborizon Group
Majority-owned by biologists and supported by its management and BPIFrance for the past 4 years, Laborizon Group is leader in medical lab testing in Western France.
IMAP is pleased to announce that BIOGROUP has acquired Laborizon Group.
Majority-owned by biologists and supported by its management and BPIFrance for the past 4 years, Laborizon Group is leader in medical lab testing in Western France. Operating 105 laboratories in Centre-Val de Loire, Brittany, Pays de la Loire and Ile-de-France, it generated a pro-forma revenue of over €160 million in 2019. Since 2016, Laborizon has doubled in size thanks to the completion of 15+ acquisitions.
BIOGROUP, which is majority-owned by Doctor Stéphane Eimer, operates over 670 labs located throughout France. The Group is the leading player in medical lab testing in France, with a pro-forma revenue of €880 million in 2019. The Group employs over 6,600 people, of which 750 are biologists.
The IMAP France (Degroof Petercam) team, led by Cyril Kammoun, acted as exclusive financial advisor to BIOGROUP. Since January 2020, this is the 5th transaction in the medical lab testing industry for the team, which has established itself as the leading player in M&A advisory and financing in this sector.
Dr. Stéphane Eimer, Chairman of BIOGROUP, declared
"Laborizon is BIOGROUP's largest acquisition to date and an important step in the group’s development. BIOGROUP is pleased to integrate Laborizon and thus, further develop in Western France. As far as I am concerned, I am looking forward to working with the Laborizon teams with whom I have developed high quality human relationships over the years. The partnership with Laborizon's biologists will enable BIOGROUP to pursue the remarkable development achieved by Laborizon over the last few years."